


Author's Accepted Manuscript

Safety and tolerability profile of daclizumab high-yield process in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies

Gavin Giovannoni, Ludwig Kappos, Ralf Gold, Bhupendra O Khatri, Krzysztof Selmaj, Kimberly Umans, Steven J Greenberg, Marianne Sweetser, Jacob Elkins, Peter McCroskery



PII: S2211-0348(16)30062-1
DOI: <http://dx.doi.org/10.1016/j.msard.2016.05.010>
Reference: MSARD403

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 22 December 2015
Revised date: 21 April 2016
Accepted date: 10 May 2016

Cite this article as: Gavin Giovannoni, Ludwig Kappos, Ralf Gold, Bhupendra O Khatri, Krzysztof Selmaj, Kimberly Umans, Steven J Greenberg, Marianne Sweetser, Jacob Elkins and Peter McCroskery, Safety and tolerability profile of daclizumab high-yield process in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies, *Multiple Sclerosis and Related Disorders*, <http://dx.doi.org/10.1016/j.msard.2016.05.010>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Safety and tolerability profile of daclizumab high-yield process in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies

Gavin Giovannoni ^{a,*}, Ludwig Kappos ^b, Ralf Gold ^c, Bhupendra O Khatri ^d, Krzysztof Selmaj ^e, Kimberly Umans ^f, Steven J Greenberg ^g, Marianne Sweetser ^{f,1}, Jacob Elkins ^f, and Peter McCroskery ^f

^a Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK. E-mail address: g.giovannoni@qmul.ac.uk

^b Neurology, Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. E-mail address: ludwig.kappos@usb.ch

^c Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Gudrunstraße 56, 44791, Bochum, Germany. E-mail address: Ralf.Gold@ruhr-uni-bochum.de

^d Center for Neurological Disorders and The Regional Multiple Sclerosis Center, Wheaton Franciscan Health Care St. Francis Hospital, 3237 S. 16th Street, Milwaukee, WI 53215, USA. E-mail address: bokhatri@aol.com;

^e Department of Neurology, Medical University of Lodz, ul. Kopcinskiego 22, 90-153 Lodz, Poland. E-mail address: kselmaj@afazja.am.lodz.pl

^f Biogen, 14 Cambridge Center, Cambridge, MA 02142, USA. E-mail addresses: kim.umans@biogen.com; msweetser@alnylam.com; peter.mccroskery@biogen.com; jake.elkins@biogen.com

^g AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. E-mail address: steven.greenberg@abbvie.com

¹ Present address: Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA. E-mail address: msweetser@alnylam.com

*** Corresponding author:** Prof. Gavin Giovannoni, Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, 4 Newark Street,

Download English Version:

<https://daneshyari.com/en/article/5912079>

Download Persian Version:

<https://daneshyari.com/article/5912079>

[Daneshyari.com](https://daneshyari.com)